都气丸加味联合噻托溴铵治疗稳定期慢性阻塞性肺疾病肺肾气虚证的临床疗效分析  

Analysis of clinical efficacy of modified Duqi Pill combined with tiotropium bromide in treating stable chronic obstructive pulmonary disease with syndrome of qi deficiency of lung and kidney

作　　者：刘清果 LIU Qing-guo(Traditional Chinese Medicine Department,Yuncheng Chengxin Hospital,Yuncheng 274700,China)

机构地区：[1]郓城诚信医院中医科,274700

出　　处：《中国现代药物应用》2024年第12期160-164,共5页Chinese Journal of Modern Drug Application

摘　　要：目的观察都气丸加味方联合噻托溴铵对稳定期慢性阻塞性肺疾病(慢阻肺)肺肾气虚证的治疗效果。方法80例稳定期慢阻肺肺肾气虚证患者,随机分为观察组与对照组,每组40例。对照组给予噻托溴铵粉雾剂吸入治疗,观察组在对照组基础上加用都气丸加味治疗。比较两组患者治疗3个月临床疗效,治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC、FEV1占预计值百分比]、中医证候积分、生活质量评分。结果治疗3个月后,观察组与对照组总有效率分别为92.5%、70.0%,观察组明显高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者FVC、FEV1、FEV1/FVC、FEV1占预计值百分比均较治疗前升高,且观察组患者FEV1(1.93±0.19)L、FVC(2.85±0.31)L、FEV1/FVC(65.21±7.05)%、FEV1占预计值百分比(67.68±7.09)%较对照组的(1.74±0.17)L、(2.69±0.29)L、(59.31±6.91)%、(60.74±6.93)%更高,差异有统计学意义(P<0.05)。治疗后,两组患者喘促气短、乏力、自汗、易感冒、腰膝酸软、夜尿频多积分较治疗前降低,且观察组患者喘促气短积分(0.74±0.54)分、乏力积分(0.81±0.23)分、自汗积分(1.24±0.29)分、易感冒积分(1.58±0.34)分、腰膝酸软积分(0.84±0.51)分、夜尿频多积分(0.88±0.54)分较对照组的(1.05±0.64)、(1.07±0.24)、(1.65±0.33)、(1.77±0.41)、(1.12±0.26)、(1.31±0.37)分更低,差异有统计学意义(P<0.05)。治疗后,两组患者躯体功能、认知功能、情绪功能、社会功能评分较治疗前升高,且观察组患者躯体功能评分(89.59±10.21)分、认知功能评分(87.23±10.09)分、情绪功能评分(85.17±10.01)分、社会功能评分(89.34±10.31)分较对照组的(77.33±10.39)、(79.22±10.08)、(72.39±10.13)、(70.88±10.11)分更高,差异有统计学意义(P<0.05)。结论稳定期慢阻肺肺肾气虚证患者临床应用都气丸加味联合噻托溴铵治疗,能够显著降低患者的各项中医证�Objective To observe the effect of modified Duqi Pill combined with tiotropium bromide in treating stable chronic obstructive pulmonary disease with syndrome of qi deficiency of lung and kidney.Methods 80 patients with chronic obstructive pulmonary disease with syndrome of qi deficiency of lung and kidney were randomly divided into an observation group and a control group,with 40 cases in each group.The control group was given tiotropium bromide powder aerosol inhalation treatment,and the observation group was given modified Duqi pill based on the control group.The clinical efficacy after 3 months of treatment,pulmonary function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC,FEV1 as a percentage of the predicted value],traditional Chinese medicine symptom score and quality of life score before and after treatment.Results After 3 months of treatment,the total effective rate of the observation group and the control group were 92.5%and 70.0%,respectively,and the observation group was significantly higher than the control group.The difference was statistically significant(P<0.05).After treatment,the FVC,FEV1,FEV1/FVC and FEV1 as a percentage of the predicted value in both groups were higher than those before treatment;the observation group had FEV1 of(1.93±0.19)L,FVC of(2.85±0.31)L,FEV1/FVC of(65.21±7.05)%,and FEV1 as a percentage of the predicted value of(67.68±7.09)%,which were higher than(1.74±0.17)L,(2.69±0.29)L,(59.31±6.91)%,and(60.74±6.93)%in the control group;the difference was statistically significant(P<0.05).After treatment,the scores of dyspnea and shortness of breath,fatigue,spontaneous sweating,susceptibility to colds,lower back and knee soreness,and nocturia frequency in both groups were lower than those before treatment;in the observation group,the scores of dyspnea and shortness of breath,fatigue,spontaneous sweating,susceptibility to colds,lower back and knee soreness,and nocturia frequency were(0.74±0.54),(0.81±0.23),(1.24±0.29),(1.58±0.34),(0.84

关 键 词：都气丸加味 噻托溴铵 稳定期 慢性阻塞性肺疾病 肺肾气虚证 临床疗效 

分 类 号：R563.9[医药卫生—呼吸系统]